"NYU Langone’s Dr. Ruth Oratz is a medical oncologist treating people who have breast cancer or are at risk of developing breast cancer."

During the past decade, Ruth Oratz MD conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 3 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ruth Oratz MD" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator, "Ortho Biotech, Inc." with 1 trials as a collaborator, "Sanofi" with 1 trials as a collaborator and "Tibotec Pharmaceutical Limited" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Ruth Oratz MD" are "Metastatic Breast Cancer" (2 trials) and "Breast Cancer" (1 trials). Many other conditions were trialed in "Ruth Oratz MD" in a lesser frequency.

Most popular intervention types in "Ruth Oratz MD" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (2 trials), "Cytoxan" (1 trials), "Herceptin" (1 trials), "Ixabepilone" (1 trials) and "Pegylated liposomal doxorubicin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ruth Oratz MD" are 2 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Ruth Oratz MD". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Ruth Oratz MD, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Ruth Oratz MD, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".